Cancer Genetics has appointed Glenn Miles its new chief financial officer, effective Nov. 26.
The Rutherford-based precision medicine company also said Igor Gitelman, chief accounting officer, is leaving to pursue other opportunities.
“Glenn joins Cancer Genetics with a wealth of financial and accounting leadership experience, which we believe will be instrumental as we continue executing on our 2018 transformation strategy and build a foundation for sustainable growth and profitability. He has a proven ability to develop and execute comprehensive financial strategies, which will enable him to play an important role in Cancer Genetics’ future. We are excited to have Glenn join the CGI team and look forward to his anticipated contributions,” John A. Roberts, Cancer Genetics CEO, said.
Miles, who has more than 30 years of experience in accounting and finance, has been a contractor for Cancer Genetics since July of this year.
Before that, he was president and chief financial officer of Catalytic Consulting LLC. Previously, he was a biopharmaceutical controller for Europe, Latin America and U.S. oncology at Pfizer. Prior to Pfizer, he held various senior-level finance roles at Lehman Brothers and AT&T Mobility. He began his career at Grant Thornton.
“I am excited to join CGI at a critical juncture for the company. Jay and his team have made impressive progress toward repositioning the company over the last several months, and I am eager to contribute to those efforts as we work to grow CGI’s business and build shareholder value,” Miles said.